-
IARC Monographs on the Evaluation of... Dec 1979
Topics: Animals; Breast Diseases; Carcinogens; Chemical Phenomena; Chemistry; Dogs; Female; Haplorhini; Humans; Medroxyprogesterone; Mice; Pregnancy; Rats; Teratogens; Uterine Cervical Neoplasms
PubMed: 120837
DOI: No ID Found -
Contraception Apr 1981Data from published studies of the quantity of medroxyprogesterone acetate and/or its metabolites in the milk of lactating women receiving Depo-Provera for contraception... (Review)
Review
Data from published studies of the quantity of medroxyprogesterone acetate and/or its metabolites in the milk of lactating women receiving Depo-Provera for contraception is extrapolated into the amount of drug ingested daily by a theoretically average infant. Comparisons are made with the results of similar studies in animals. Fetal metabolism of medroxyprogesterone acetate is reviewed. Embryonic and fetal development of the human reproductive system is discussed. Results of studies of the effects of steroidal hormones, particularly medroxyprogesterone acetate, on mental development and sexual dimorphic behavior after exposure in utero are presented. It is concluded that the very small amount of drug and/or its metabolites ingested by the nursing infant via breast milk is highly unlikely to have any significant effect on the nursing infant.
Topics: Animals; Delayed-Action Preparations; Female; Fetus; Humans; Infant; Infant, Newborn; Lactation; Medroxyprogesterone; Medroxyprogesterone Acetate; Milk, Human; Pregnancy; Rats
PubMed: 6456130
DOI: 10.1016/0010-7824(81)90027-5 -
Lancet (London, England) Mar 1983
Clinical Trial
Topics: Abortion, Threatened; Clinical Trials as Topic; Corpus Luteum; Drug Evaluation; Female; Fertilization in Vitro; Humans; Medroxyprogesterone; Pregnancy
PubMed: 6132069
DOI: 10.1016/s0140-6736(83)92004-4 -
Bulletin of the World Health... 1986A review of all available data including those from the WHO Collaborative Study of Neoplasia and Steroid Contraceptives has shown no increased risk of cancers of the... (Review)
Review
A review of all available data including those from the WHO Collaborative Study of Neoplasia and Steroid Contraceptives has shown no increased risk of cancers of the breast, endometrium, ovary or liver in women using depot-medroxyprogesterone acetate (DMPA). The issue of a causal association between DMPA use and cervical cancer is as yet unresolved and will require the accumulation of additional data. To date, in the WHO study only a small number of women have used DMPA for prolonged periods or have had a long interval since first use. Information on cancer risk in these women can only be gained by continuing the present study or by initiating additional studies focused on these specific topics.
Topics: Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasms; Risk
PubMed: 2945666
DOI: No ID Found -
Journal of the American Academy of... Feb 2004To present current data on bone mineral density (BMD) in adolescent women using the long-acting contraceptive depot medroxyprogesterone acetate (DMPA) and also to... (Review)
Review
PURPOSE
To present current data on bone mineral density (BMD) in adolescent women using the long-acting contraceptive depot medroxyprogesterone acetate (DMPA) and also to discuss the importance of developing maximal bone mass during adolescence to offset bone demineralization later in life.
DATA SOURCES
Research-based articles in the medical literature, review articles, and recommendations from the American Academy of Pediatrics and the National Osteoporosis Foundation.
CONCLUSIONS
Osteoporosis is a preventable disease that affects millions of Americans, particularly older women. Factors influencing the attainment and maintenance of peak bone mass during childhood and adolescence affect the future risk of fractures. Although longitudinal studies conducted on adolescent women using DMPA are very limited, findings suggest that adolescents are losing bone density during a time of expected bone accretion.
IMPLICATIONS FOR PRACTICE
Clinicians must consider all the risks and benefits when prescribing contraceptives to adolescents. By themselves, the findings related to BMD and DMPA use by adolescents are not sufficient to limit the use of DMPA as a contraceptive method. However, clinicians must take into account the addition of other modifying factors associated with BMD that may contribute to overall bone loss in adolescent females. More prospective data on the long-term use of DMPA by adolescents are needed to determine DMPA's effect on bone loss and to determine if bone loss is transient in adolescents.
Topics: Adolescent; Bone Density; Female; Humans; Medroxyprogesterone; Osteoporosis; Risk Factors
PubMed: 15055422
DOI: 10.1111/j.1745-7599.2004.tb00373.x -
Lancet (London, England) Jul 1982The haematological and clinical effects of medroxyprogesterone acetate in homozygous sickle-cell (SS) disease were assessed in a 2-year controlled crossover trial... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
The haematological and clinical effects of medroxyprogesterone acetate in homozygous sickle-cell (SS) disease were assessed in a 2-year controlled crossover trial completed by 23 patients. Haematological indices remained steady during the placebo phase, but during the medroxyprogesterone-acetate phase fetal haemoglobin, total haemoglobin, red-cell mass, and red-cell survival rose significantly, and reticulocytes, irreversibly-sickled-cell counts, and total bilirubin fell significantly. Painful crises were significantly less frequent during the medroxyprogesterone-acetate than the placebo phase. These results are compatible with an inhibition of in-vivo sickling in patients with SS disease during medroxyprogesterone-acetate treatment. The mechanisms of such an effect require further study.
Topics: Adult; Anemia, Sickle Cell; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Aging; Erythrocyte Count; Erythrocytes; Female; Fetal Hemoglobin; Homozygote; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menstruation; Random Allocation
PubMed: 6178915
DOI: 10.1016/s0140-6736(82)90320-8 -
Steroids Dec 2020The fungal transformations of medroxyrogesterone (1) were investigated for the first time using Cunninghamella elegans, Trichothecium roseum, and Mucor plumbeus. The...
Medroxyprogesterone derivatives from microbial transformation as anti-proliferative agents and acetylcholineterase inhibitors (combined in vitro and in silico approaches).
The fungal transformations of medroxyrogesterone (1) were investigated for the first time using Cunninghamella elegans, Trichothecium roseum, and Mucor plumbeus. The metabolites obtained are as following: 6β, 20-dihydroxymedroxyprogesterone (2), 12β-hydroxymedroxyprogesterone (3), 6β, 11β-dihydroxymedroxyprogesterone (4), 16β-hydroxymedroxyprogesterone (5), 11α, 17-dihydroxy-6α-methylpregn-4-ene-3, 20-dione (6), 11-oxo-medroxyprogesterone (7), 6α-methyl-17α-hydroxypregn-1,4-diene-3,20-dione (8), and 6β-hydroxymedroxyprogesterone (9), 15β-hydroxymedroxyprogesterone (10), 6α-methyl-17α, 11β-dihydroxy-5α-pregnan-3, 20-dione (11), 11β-hydroxymedroxyprogesterone (12), and 11α, 20-dihydroxymedroxyprogesterone (13). Among all the microbial transformed products, the newly isolated biotransformed product 13 showed the most potent activity against proliferation of SH-SY5Y cells. Compounds 12, 5, 6, 9, 11, and 3 (in descending order of activity) also showed some extent of activity against SH-SY5Y tumour cell line. The never been reported biotransformed product, 2, showed the most potent inhibitory activity against acetylcholinesterase. Molecular modelling studies were carried out to understand the observed experimental activities, and also to obtain more information on the binding mode and the interactions between the biotransformed products, and enzyme.
Topics: Animals; Biotransformation; Caenorhabditis elegans; Cell Proliferation; Cholinesterase Inhibitors; Computer Simulation; Cunninghamella; Hypocreales; In Vitro Techniques; Medroxyprogesterone; Molecular Docking Simulation; Spectrum Analysis
PubMed: 32976918
DOI: 10.1016/j.steroids.2020.108735 -
Cancer Treatment Reviews Sep 1988
Review
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Humans; Kidney Neoplasms; Medroxyprogesterone; Medroxyprogesterone Acetate
PubMed: 2974757
DOI: 10.1016/0305-7372(88)90003-5 -
Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.Clinical Pharmacokinetics Mar 1989
Review
Topics: Antineoplastic Agents; Biological Availability; Breast Neoplasms; Drug Compounding; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate
PubMed: 2524303
DOI: 10.2165/00003088-198916030-00001 -
JAMA Jan 1973
Topics: Acromegaly; Humans; Medroxyprogesterone
PubMed: 4739130
DOI: No ID Found